Mitsubishi Tanabe steps further back from blood products
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) is moving its business further away from blood products and focusing on its core prescription drug operations through a decision to stop handling preparations from the Japan Blood Products Organization (JBPO).
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.